Advanced search

African trypanosomiasis and antibodies : implications for vaccination, therapy and diagnosis

Stefan Magez (UGent) and Magdalena Radwanska (UGent)
(2009) FUTURE MICROBIOLOGY. 4(8). p.1075-1087
Author
Organization
Abstract
African trypanosomiasis causes devastating effects on human populations and livestock herds in large parts of sub-Saharan Africa. Control of the disease is hampered by the lack of any efficient vaccination results in a field setting, and the severe side effects of current drug therapies. In addition, with the exception of Trypanosoma brucei gambiense infections, the diagnosis of trypanosomiasis has to rely on microscopic analysis of blood samples, as other specific tools are nonexistent, However, new developments in biotechnology, which include loop-mediated isothermal amplification as an adaptation to conventional PCR, as well as the antibody engineering that has allowed the development of Nanobody (R) technology, offer new perspectives in both the detection and treatment of trypanosomiasis. In addition, recent data on parasite-induced B-cell memory destruction offer new insights into mechanisms of vaccine failure, and should lead us towards new strategies to overcome trypanosome defenses operating against the host immune system.
Keywords
African trypanosomiasis, antibody, diagnosis, drug-targeting, Nanobody (R), sleeping sickness, vaccination, INVARIANT SURFACE GLYCOPROTEINS, BLOOD-STREAM FORMS, SLEEPING-SICKNESS SUSPECTS, SINGLE-DOMAIN ANTIBODIES, NECROSIS-FACTOR-ALPHA, BRUCEI-RHODESIENSE, BOVINE TRYPANOSOMIASIS, MONOCLONAL-ANTIBODIES, CONGOLENSE INFECTION, NANOBODY TECHNOLOGY

Citation

Please use this url to cite or link to this publication:

Chicago
Magez, Stefan, and Magdalena Radwanska. 2009. “African Trypanosomiasis and Antibodies : Implications for Vaccination, Therapy and Diagnosis.” Future Microbiology 4 (8): 1075–1087.
APA
Magez, S., & Radwanska, M. (2009). African trypanosomiasis and antibodies : implications for vaccination, therapy and diagnosis. FUTURE MICROBIOLOGY, 4(8), 1075–1087.
Vancouver
1.
Magez S, Radwanska M. African trypanosomiasis and antibodies : implications for vaccination, therapy and diagnosis. FUTURE MICROBIOLOGY. 2009;4(8):1075–87.
MLA
Magez, Stefan, and Magdalena Radwanska. “African Trypanosomiasis and Antibodies : Implications for Vaccination, Therapy and Diagnosis.” FUTURE MICROBIOLOGY 4.8 (2009): 1075–1087. Print.
@article{8528986,
  abstract     = {African trypanosomiasis causes devastating effects on human populations and livestock herds in large parts of sub-Saharan Africa. Control of the disease is hampered by the lack of any efficient vaccination results in a field setting, and the severe side effects of current drug therapies. In addition, with the exception of Trypanosoma brucei gambiense infections, the diagnosis of trypanosomiasis has to rely on microscopic analysis of blood samples, as other specific tools are nonexistent, However, new developments in biotechnology, which include loop-mediated isothermal amplification as an adaptation to conventional PCR, as well as the antibody engineering that has allowed the development of Nanobody (R) technology, offer new perspectives in both the detection and treatment of trypanosomiasis. In addition, recent data on parasite-induced B-cell memory destruction offer new insights into mechanisms of vaccine failure, and should lead us towards new strategies to overcome trypanosome defenses operating against the host immune system.},
  author       = {Magez, Stefan and Radwanska, Magdalena},
  issn         = {1746-0913},
  journal      = {FUTURE MICROBIOLOGY},
  language     = {eng},
  number       = {8},
  pages        = {1075--1087},
  title        = {African trypanosomiasis and antibodies : implications for vaccination, therapy and diagnosis},
  url          = {http://dx.doi.org/10.2217/fmb.09.65},
  volume       = {4},
  year         = {2009},
}

Altmetric
View in Altmetric
Web of Science
Times cited: